Helen Bernie, DO, MPH, an assistant professor of urology at Indiana University School of Medicine, will join a U.S. Food and Drug Administration (FDA) panel focused on testosterone replacement therapy and men's health. The expert panel is scheduled to meet on Wednesday, December 10.
Bernie brings clinical expertise in men's reproductive health, which is also the focus of her academic research. She will serve as a clinical expert during the discussion.
"This panel represents a critically important step forward for men's health," Bernie said. "Testosterone is not a lifestyle drug - it is a biomarker and therapeutic tool with significant implications for mortality, cardiometabolic health, mobility, cognition, and overall well-being."
She also expressed appreciation for being part of the panel: "I am grateful for the opportunity to contribute to this national discussion and to advocate for evidence-based, patient-centered recommendations that will shape the future of care for millions of men," she said.
